Literature DB >> 9042322

New avenues in 3-D computerised (stereopathological) imaging of breast cancer (review).

J D Davies1, C N Chinyama, M G Jones, S M Astley, S P Bates, J Kulka.   

Abstract

Multimodal methods of three-dimensional (3-D) imaging of breast cancer are described. These involve scanning confocal microscopy, using 50 MHz acoustic or near-infrared images, four-view (tetrahedral) radiography and x-ray projection microscopy. Computerised volume data from these techniques can be used to produce three-dimensional images of tissue ranging from 500 microns to approximately 4 mm in thickness. Preliminary findings indicate that stereoscopic images or 3-D computerised reconstructions are capable of advancing the understanding of the structure of ductal carcinoma in situ, lesions simulating microinvasive breast carcinoma, surgical clearance of high-grade calcifying ductal carcinoma in situ, and the 3-D growth patterns of invasive forms of breast carcinoma. In the future computerised image fusion techniques seem likely to be able to take advantage of multimodal imaging of breast cancers, thus correcting primary imaging artefacts, improving robustness, and combining complementary information. In addition, the use of computerised tetrahedral radiography may change the intraoperative assessment of breast cancers, which mostly depend at present upon subsequent laboratory procedures that take days to perform.

Entities:  

Mesh:

Year:  1996        PMID: 9042322

Source DB:  PubMed          Journal:  Anticancer Res        ISSN: 0250-7005            Impact factor:   2.480


  2 in total

1.  Cytokeratin demonstration in thick breast tissue slices.

Authors:  J D Davies; S H Sharp; C N Chinyama
Journal:  Histochem J       Date:  1997-05

2.  Automated reconstruction algorithm for identification of 3D architectures of cribriform ductal carcinoma in situ.

Authors:  Kerri-Ann Norton; Sameera Namazi; Nicola Barnard; Mariko Fujibayashi; Gyan Bhanot; Shridar Ganesan; Hitoshi Iyatomi; Koichi Ogawa; Troy Shinbrot
Journal:  PLoS One       Date:  2012-09-06       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.